The large majority of patients regain their perception of shapes, objects and the movement around them, which means they can regain a certain degree of interrelation with themselves and independent movement. RP is a progressive condition, which means that your sight will continue to get worse over the years.
This camera captures images that will be processed and they reach the brain's ocicptal cortex via a stimulation system. The systeme uses glasses to hold a High Definition camera which is placed on the end of the nose. The ARGUS system is based on placing an intraocular implant that acts as an electronic epirretinal stimulus, that is to say, it is put on the surface of retina. Photoreceptor cells capture and process light helping us to see. RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). It was implanted in Spain for the first time at the Barraquer Ophthalmology Centre by Dr. Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye).
The way in which your sight is affected depends on the type of IRD you have. In the usual course of disease, the light-sensitive structures called rods which are the visual receptors used in dim lightare destroyed early on, causing night blindness in youth. This condition changes how the retina responds to light, making it hard to see. Their results earned approval from the FDA (Food and Drug Administration) in the USA in February 2013 for it to be used on patients with retinitis pigmentaria. Retinitis pigmentosa (RP) is the most common group of IRD, but there are others that have different names, and which may lead to different patterns of sight loss. retinitis pigmentosa, group of hereditary eye diseases in which progressive degeneration of the retina leads to severe impairment of vision. Retinitis pigmentosa (RP) is a group of eye problems that affect the retina. Second Sight (USA) developed an electronic retinal prothesis system providing artificial vision in 2007 using the ARGUS I and in 2009 the ARGUS II. Neuroprotective therapies, treatments with stem cells or gene therapy represent a significant future for the treatment of this pathology, although its current therapeutic options are limited.
0 kommentar(er)
